Apr. 3, 2025 — Drug-carrying DNA aptamers can deliver a one-two punch to leukemia by precisely targeting the elusive cancer stem cells that seed cancer relapses, researchers report. The aptamers ...

In March 2025, Juventas Cell Therapy Ltd. conducted a phase Ib/II trial to evaluate the safety and efficacy of CNCT19 ...

Leukemia often results in severe anemia, which may significantly contribute to patient mortality and morbidity. However, the mechanisms underlying defective erythropoiesis in leukemia have not ...

Allogeneic hematopoietic stem-cell transplantation (HSCT) remains one of the only curative therapies for acute leukemias, myelodysplasia and high-risk lymphoproliferative disorders. The efficacy of ...

Over four hundred people, 80% of them being children under 14 years old, will be diagnosed with B-cell Acute Lymphoblastic ...

Patients with acute myeloid leukemia who relapse after stem cell transplantation have just a small chance of survival: doctors can give them additional donor T cells to fight the cancer, but only ...

DelveInsight’s, “Acute Myeloid Leukemia Pipeline Insight” report provides comprehensive insights about 110+ companies and 120+ pipeline drugs in Acute Myeloid Leukemia pipeline landscape.

During a Case-Based Roundtable® event, John N. Allan, MD, discussed how new regimens using BTK inhibitors and venetoclax ...